Skip to main navigation Skip to content

Search whole site

Back to all Current clinical trials
GOLSEEK-2 - Golcadomide plus Rituximab for Follicular Lymphoma

Patients newly diagnosed with advanced follicular lymphoma with be randomised to standard treatment or Golcadomide and Rituximab. Will be 1:1:1 as will be 2 doses of Golcadomide. 

  • Category
  • Trial status
    Active, not recruiting
  • Trial phase
    Phase 2 Drug Trial
    Early stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
  • Registry listing
  • ERM Project ID
    111193

Trial contact details

What you need to know

Inclusion
- Histologically confirmed follicular lymphoma as per standards
- No prior systemic treatment for follicular lymphoma
- Needs treatment as per investigator
- Measurable disease
Exclusion
- Transformed lymphoma
- CNS involvement
- Other subtype of lymphoma
 

What is involved for me?

Days 1 -14 Golcadomide plus rituximab for 12 cycles  (1 cycle 4 weeks) - then maintenance rituximab - weekly visit first cycle then 2 weekly for cycle 2 then monthly
6 cycles of chemo if this arm.
Regular scanning every 12 weeks
Completion questionnaires monthly first 12 months then every 16 weeks.

Back to all Current clinical trials